Status:
COMPLETED
The Effect of Mandibular Advancement Devices on Markers of Cardiovascular Health in Obstructive Sleep Apnea Patients
Lead Sponsor:
University of Alberta
Conditions:
Obstructive Sleep Apnea
Eligibility:
All Genders
18-70 years
Brief Summary
Obstructive sleep apnea (OSA) is a type of disordered breathing defined by the repetitive obstruction of airflow during sleep due to upper airway collapse. Each obstructive event contributes to decrea...
Detailed Description
In OSA the obstruction of breathing can be either partial (hypopnea) or complete (apnea), and each obstructive event contributes to decreased blood oxygen, or hypoxia. Sleep disordered breathing and n...
Eligibility Criteria
Inclusion
- Between ages of 18-70
- Diagnosed with Obstructive Sleep Apnea and prescribed with Mandibular Advancement Device
- No medical history of cardiovascular, pulmonary, renal diseases
Exclusion
- Any known cardiovascular, respiratory or pulmonary disease
- Have a history of smoking regularly in past 6 months
- Pre-existing symptomatic non-respiratory sleep disorder (restless leg syndrome, chronic insomnia)
- if more than 50% of their observed apneas are due to sleep apnea
Key Trial Info
Start Date :
July 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 9 2024
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05387122
Start Date
July 11 2021
End Date
September 9 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2R3